Pharvaris (PHVS) Change in Taxes (2021 - 2026)
Pharvaris' (PHVS) quarterly Change in Taxes came in at -$150365.9 in Q1 2026, down 163.74% YoY from $235894.6 in Q1 2025, and up 93.81% on a QoQ basis from -$2.4 million in Q4 2025.
Pharvaris (PHVS) Change in Taxes (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 6 years of Change in Taxes data on file, last reported at -$150365.9 in Q1 2026.
- Quarterly Change in Taxes fell 163.74% year-over-year to -$150365.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (down 100.01% YoY) and the FY2025 annual result came in at -$2.5 million, up 18.19% from the prior year.
- Change in Taxes advanced to -$150365.9 in Q1 2026, from -$2.4 million in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $1224.2 billion in Q3 2024 to a low of -$1200.5 billion in Q2 2024.
- A 5-year average of $1.8 billion and a median of -$150365.9 in 2026 frame the typical range for Change in Taxes.
- Annual changes were most pronounced in 2022 — Change in Taxes plunged 16004.73% — and 2023, when it surged 207225949.77%.
- Tracing PHVS's Change in Taxes over 5 years: stood at $17565.6 in 2022, then tumbled by 1801.86% to -$298941.3 in 2023, then slumped by 48.96% to -$445296.5 in 2024, then tumbled by 445.88% to -$2.4 million in 2025, then soared by 93.81% to -$150365.9 in 2026.
- The last three Change in Taxes figures came in at -$150365.9 (Q1 2026), -$2.4 million (Q4 2025), and $235894.6 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150,365.89 |
| Mar 31, 2026 | -150,365.89 |
| Dec 31, 2025 | -2.43 Mn |
| Dec 31, 2025 | -2.43 Mn |
| Mar 31, 2025 | 235,894.55 |
| Mar 31, 2025 | 235,894.55 |
| Dec 31, 2024 | -445,296.53 |
| Dec 31, 2024 | -445,296.53 |
| Sep 30, 2024 | 1,224.25 Bn |
| Sep 30, 2024 | 1,224.25 Bn |
| Jun 30, 2024 | -1,200.47 Bn |
| Jun 30, 2024 | -1,200.47 Bn |
| Mar 31, 2024 | -65,184.97 |
| Mar 31, 2024 | -65,184.97 |
| Dec 31, 2023 | -298,941.30 |
| Dec 31, 2023 | -298,941.30 |
| Sep 30, 2023 | 417.97 Bn |
| Sep 30, 2023 | 417.97 Bn |
| Jun 30, 2023 | -418.10 Bn |
| Jun 30, 2023 | -418.10 Bn |